Notes: VAF347 is an agonist of the aryl hydrocarbon receptor (AhR).{64824} It binds to AhR in a radioligand binding assay using guinea pig hepatic cytosol and induces mRNA expression of the AhR target gene CYP1A1 in isolated human peripheral blood mononuclear cells (PBMCs) when used at a concentration of 50 nM. VAF347 (20 µM) inhibits differentiation of HL-60 leukemia cells induced by 1,25-dihydroxy vitamin D3 (calcitriol; Item No. 71820) and promotes differentiation of HL-60 cells induced by all-trans retinoic acid (Item No. 11017).{64825} It decreases serum IgE levels and lung and bronchoalveolar lavage fluid (BALF) eosinophil infiltration in an ovalbumin-induced mouse model of allergic inflammation when administered at a dose of 30 mg/kg.{64826} VAF347 (30 mg/kg) also prevents retinal capillary degeneration in a mouse model of diabetic retinopathy induced by streptozotocin (STZ; Item No. 13104).{64827}